-Manuscript ID: bmjopen-2016-015536 -Title: Clinical characteristics of importance to outcome in patients with spondyloarthritis: Protocol for a prospective, descriptive and exploratory cohort study -Reviewer: del Río-Martínez PS -Revision: It´s a very interesting work about a complex issue such as pain and it´s mechanism in SpA. This novel focus of pain is one of the strong points of the work, as well as an exhaustive collection of data, and, as originial contribution, the assistance from patients representatives in the design of the study. The title does not reflect completely the aim of the study, A more definite title would contribute to a better difussion of the work. In the abstract, the aim is to explore clinical characteristic of importance to outcome in patients with axial SpA, although in "Participants" patients could be diagnosed with any disease of SpA spectrum, and in inclusion criteria, patients "diagnosed with SpA according to ASAS" are included. It´s not clear enough if the term SpA is referred to all SpA groups or just to axial disease. Expecting the results and their interpretation, several aspects should be consider: -The PDQ could be a useful tool for neuropathic pain, nevertheless central pain sensitisation includes a wider concept including nociceptive pain. It´s extremely difficult to value this concept, and authors include data of interest such us tender points, depression, Charlson index or SF-36, and use 1990 ACR criteria for the diagnosis of fibromyalgia. Although these criteria were useful for research and clinical trials, ACR 2010 criteria keep in mind somatic symptoms that include more aspects in the complex concept of central sensitisation.
-Considering the wide range of age as inclusion criteria (≥ 18 and ≤80), a considerable group of patients could suffer from degenerative lumbar pathologies, producing neuropathic pain, that could generate higher scores in the PDQ test. -The patients with SpA consider for biological treatment (TB), and specially those that have failed to a previous TB, have more severe forms of the disease, and pain and disabilty could be noticed as more serious. The scores of scales measuring pain, disability and quality of life are expected to be higher in these patients. -As the authors show, the sample size is a limitation that could generate a heterogeneous group. This could limit the extrapolation to other populations. -As is expressed in the conclusions, "the study may add knowledge to the current black box of complexities around the disease measures and prognosis", but as they continue "the efficacy of biologics" is a complex issue conditioned by numerous factors, such us immunogenicity and others. These factors should be of interest when interpreting the results. At last, as is mentioned by the authors, a more individualised biopsychosocial model is needed in the future management strategy. Although this will be the first study of this nature using PDQ, it is certainly unknown what would be its value as prognostic factor. Back pain and sacroiliac joint pain might be the results of something much more complex that distinguishing neuropathic from inflammatory pain. We are used to consider mechanical and inflammatory back pain, but no neurophatic type of pain. I have doubts about the value of any questionnaire in such a complex clinical situation. Nevertheless, this is one study and I don't think it should be merged with the second one Prognostic factors of response to treatment have been developed by several groups through the years. In this sense, this is not a very original project since we have data on early SpA, advanced SpA, etc, resulting from the analysis of cohorts, randomized clinical trials, and databases. Sample size should be adjusted to variables explored in this analysis Regarding variables, I would suggest the inclusion of EUROQoL and MASES instead of SPAARC for enthesitis I also would like to suggest you to search for fibromyalgia in this study Please clarify if you are planning to include patients with axSpA imaging and clinical arms of the ASAS criteria. Perhaps I did not understand very well, but there is only one biologic agent available for patients with axSPA in Sweden. Is that correct? how could you assess switching if infliximab is the only biologic you've got? Finally, I think three months would not be enough for a study like this. I would suggest at least 52 weeks of followup. I would have thought that dome patients with neuropathic pain would have a "placebo like response" in the initial weeks of treatment.
REVIEWER

VERSION 1 -AUTHOR RESPONSE
Reviewer 1. Comment 1: This is a very nice protocol aiming to explore whether high levels of neuropathic pain (e.g. fibromyalgia) have an impact on TNF alpha treatment effect in axial SpA in clinical practice The question is VERY relevant. However, although it appears as the main objective in the introduction, it is not stated as the main analysis... I would strongly recommend to highlight that the main objective is to evaluate the impact of neuropathic pain in TNF effectiveness in axSpA, and the secondary objectives are the evaluation of the other potentially associated factors (already reported in several RTC and longitudinal trials).
Answer 1: Thank you for this important comment, we certainly agree with your point of view. We have highlighted that our main objective is to evaluate the impact of neuropatic pain in TNF effectiveness in axSpA Actions: "The primary objective is to explore the prognostic value of the PDQ regarding treatment response in patients with axSpA 3 months after initiating a biological agent. Secondary aim is to evaluate the impact of extra-articular manifestations, comorbidities, and patientreported outcomes and elucidate if these factors -influence treatment response" Reviewer 2: Comment 1: The title does not reflect completely the aim of the study, A more definite title would contribute to a better difussion of the work. In the abstract, the aim is to explore clinical characteristic of importance to outcome in patients with axial SpA, although in "Participants" patients could be diagnosed with any disease of SpA spectrum, and in inclusion criteria, patients "diagnosed with SpA according to ASAS" are included. Comment 2: The PDQ could be a useful tool for neuropathic pain, nevertheless central pain sensitisation includes a wider concept including nociceptive pain. It´s extremely difficult to value this concept, and authors include data of interest such us tender points, depression, Charlson index or SF-36, and use 1990 ACR criteria for the diagnosis of fibromyalgia. Although these criteria were useful for research and clinical trials, ACR 2010 criteria keep in mind somatic symptoms that include more aspects in the complex concept of central sensitisation. Answer 2: Good comments. We agree with you that the PDQ could be a useful tool for neuropathic pain. We understand your concern regarding neuropathic pain includes a wider concept. The PDQ is validated as a screening tool for the likelihood of a neuropathic pain component. We are aware of, that other factors (e.g. fibromyalgia/ psychological processes/nociceptive pain) can influence the PDQ score, and we will take this into account in the interpretation. However, our study design allows an explanatory investigation of pain mechanisms and we find our strategy appropriate given the heterogeneity of axSpA and the sparse knowledge currently available within this field of research. Comment 3: Considering the wide range of age as inclusion criteria (≥ 18 and ≤80), a considerable group of patients could suffer from degenerative lumbar pathologies, producing neuropathic pain, that could generate higher scores in the PDQ test Answer 3: Thank you for addressing this issue. We agree that the elder participants can suffer from degenerative lumbar pathologies which can generate a higher PDQ score, as the likelihood of a neuropathic pain component in this condition might be high. However, we do not see this issue as a limitation. Regardless of the reason for a high PDQ score, we still hypothesize a poorer treatment response among patients with a high PDQ score, compared to patients with a low score. Comment 4: The patients with SpA consider for biological treatment (TB), and specially those that have failed to a previous TB, have more severe forms of the disease, and pain and disabilty could be noticed as more serious. The scores of scales measuring pain, disability and quality of life are expected to be higher in these patients. Answer 4: That is an important notion, thank you. Participants will be divided into two groups, A and B. Group A: naive to any biologics (including patients newly diagnosed with ax-SpA), group B: switching therapy (Figure 3) . We are aware of the scores regarding disability, quality of life and pain (VAS-pain) might be higher in group B. However, we do not think that a more severe form of the disease influence on the PDQ score, giving that the PDQ score is based on a "non-inflammatory pain component". Comment 5: As the authors show, the sample size is a limitation that could generate a heterogeneous group. This could limit the extrapolation to other populations. Answer 5: We acknowledge that heterogeneity is a limitation. Actions: We will take the above into account, when we interpret our results. Comment 6: As is expressed in the conclusions, "the study may add knowledge to the current black box of complexities around the disease measures and prognosis", but as they continue "the efficacy of biologics" is a complex issue conditioned by numerous factors, such us immunogenicity and others. These factors should be of interest when interpreting the results. At last, as is mentioned by the authors, a more individualised biopsychosocial model is needed in the future management strategy Answer 6: Thank you for the comment. We agree that many factors can influence the treatment response, including immunogenicity. . Should we keep the idea of a group of diseases, we could back to the concept of undifferentiated SpA, ankylosing spondylitis, psoriatic arthritis, etc., and have serious problems, including sampling. We should also be careful with the concept of radiographic and non-radiographic axSpA since not all patients with axSpA are expected to develop radiographic sacroiliitis and syndemosphytes. That means that we are not facing different stages of a disease, but different forms of axSpA (Deodhar A, et al. Ann Rheum Dis2016; 75:791-4) Answer 1: Whether non radiographic-ax-SpA (nr-ax-SpA) and ankylosing spondylitis (AS) should be considered the same disease is currently debated. We use the Assessment of SpondyloarthritisInternational Society (ASAS) classifications criteria for ax-SpA (imaging arm) and the Modified New York criteria for AS. Actions: Inclusion criteria: "Patients diagnosed with axSpA according to ASAS (imaging arm)"
Comment 2:
The objective of the study is to determine the value painDETECT questionnaire and/or other baseline characteristics as prognostic factors for treatment response in patients with axSpA starting or switching a biologic agent. Responses will be assessed 3 months after the onset of biological treatment Sample size was calculated according to PDQ categories Concerns about item number 2 I see two different studies: one based on PDQ and another on demographic and clinical characteristics. Although this will be the first study of this nature using PDQ, it is certainly unknown what would be its value as prognostic factor. Back pain and sacroiliac joint pain might be the results of something much more complex that distinguishing neuropathic from inflammatory pain. We are used to consider mechanical and inflammatory back pain, but no neurophatic type of pain. I have doubts about the value of any questionnaire in such a complex clinical situation. Nevertheless, this is one study and I don't think it should be merged with the second one Prognostic factors of response to treatment have been developed by several groups through the years. In this sense, this is not a very original project since we have data on early SpA, advanced SpA, etc, resulting from the analysis of cohorts, randomized clinical trials, and databases. Sample size should be adjusted to variables explored in this analysis Answer 2: Thank you for your comments. We understand your concern regarding two different study types: one based on PDQ and another on clinical characteristics. Our main objective is to evaluate the impact of neuropathic pain in biological treatment effectiveness in axSpA patients, and the secondary objectives are the evaluation of the other potentially associated factors (already reported in RCT studies). As many factors influence treatment response, we want to illuminate both the clinical characteristics of the axSpA patients as well as the impact of the pain phenotypes. We understand your concern regarding neuropathic pain includes a wider concept. The PDQ is validated as a screening tool for the likelihood of a neuropathic pain component. We know that other factors (e.g. fibromyalgia/ psychological processes/nociceptive pain) can influence the PDQ score, and we will take this into account in the interpretation. However, our study design allows an explanatory investigation of pain mechanisms and we find our strategy appropriate given the heterogeneity of axSpA and the sparse knowledge currently available within this field of research. Actions: We have highlighted our objectives: Abstract: "The primary objective is to investigate the prognostic value of the PDQ regarding treatment response in patients with axSpA ≥ 3 months after initiating a biological agent. Secondary aim is to evaluate the impact of extra-articular manifestations, comorbidities, and patientreported outcomes and elucidate if these factors -influence treatment response" Objectives: "Our primary objective is to determine whether classification from the painDETECT Questionnaire is valuable as prognostic factor for treatment response in patients diagnosed with axSpA initiating or switching treatment with a biological agent. Secondary aim is to evaluate the impact of extra-articular manifestations, comorbidities evaluated by Charlson score, and patient-reported outcomes and elucidate if these factors -independently or by interaction -influence treatment response" Comment 3: Regarding variables, I would suggest the inclusion of EUROQoL and MASES instead of SPAARC for enthesitis . I also would like to suggest you to search for fibromyalgia in this study Answer 3: Thank you for your suggestions regarding variables. Entheses is a core set domain in clinical trials with axSpA patients, according to the Assessment of SpondyloArthritis international Society (ASAS)/OutcomeMeasures in Rheumatology Clinical Trails (OMERACT). However, there is no consensus of which instrument to use. The feasibility for MASES and SPARCC are equally. We are searching for fibromyalgia in our study, using the 1990 ACR criteria.
Comment 4: Please clarify if you are planning to include patients with axSpA imaging and clinical arms of the ASAS criteria.
Answer 4: We are using the imaging arm. Actions:
Inclusion criteria: "Patients diagnosed with axSpA according to ASAS (imaging arm)"
Comment 5: Perhaps I did not understand very well, but there is only one biologic agent available for patients with axSPA in Sweden. Is that correct? how could you assess switching if infliximab is the only biologic you've got?
Answer 5: We do not only have infliximab in Denmark. We have a treatment guideline developed by The Danish Council for the use of expensive hospital medicines (RADS). Currently first line therapy is a biosimilar infliximab compound (Remsima®, Orion Pharma). Second and third line therapy depends on comorbidity (e.g. Inflammatory bowel disease, anterior uveitis, psoriasis). Comment 6: Finally, I think three months would not be enough for a study like this. I would suggest at least 52 weeks of followup. I would have thought that dome patients with neuropathic pain would have a "placebo like response" in the initial weeks of treatment Answer 6: We agree that a three month follow-up could be a limitation, however, according to ASAS, the recommendations state that reassessment of treatment effect should be done after 3 months.
